T
TargImmune Therapeutics
Biotech & Life Sciences · Basel, Switzerland · Founded 2016
Developing novel targeted immuno-oncology drugs MoreLess
TargImmune Therapeutics AG is a Swiss-based biotechnology startup focused on revolutionizing cancer treatment. The company is dedicated to significantly improving the survival rates of cancer patients through its innovative portfolio of oncology compounds. TargImmune operates in the highly specialized and competitive field of cancer therapeutics, targeting a global market that includes hospitals, research institutions, and pharmaceutical companies.
The core of TargImmune's business model is its groundbreaking modular, synthetic, targeted nucleic acid delivery platform. This platform is the first of its kind, known as Targeted Apoptosis and Immune Modulators (TAIMs). It uses synthetic nanoparticles to deliver nucleic acid therapeutics directly to cancer cells. Nucleic acids are molecules that carry genetic information, and by targeting these directly, TargImmune aims to induce apoptosis (cell death) in cancer cells and modulate the immune system to better fight cancer.
TargImmune generates revenue through the development and commercialization of its proprietary cancer treatment compounds. The company collaborates with pharmaceutical firms and research institutions, licensing its technology and forming strategic partnerships to bring its treatments to market. Additionally, TargImmune is open to discussions with potential investors to secure funding for further research and development.
The company's leadership team, including Chairman Dr. Kuno Sommer and Vice Chairman Dr. Peter Kash, brings a wealth of experience and scientific expertise, which is crucial for navigating the complexities of cancer treatment development. TargImmune is actively expanding its team to meet its ambitious goals and welcomes approaches from professionals interested in joining their mission.
In summary, TargImmune Therapeutics AG is a pioneering biotech company dedicated to transforming cancer treatment through its novel targeted nucleic acid delivery platform, aiming to improve patient survival rates and outcomes.
Keywords: Cancer Treatment, Biotechnology, Nucleic Acid Delivery, Oncology, Synthetic Nanoparticles, TAIMs, Apoptosis, Immune Modulation, Pharmaceutical Partnerships, Swiss Startup.
Company overview
TargImmune Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Basel, Switzerland
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 59.5
Valuation & funding
TargImmune Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2025 | $0 | — | Ioncologi | ↗ |
| EARLY VC✓Equity / VC | Jul 2021 | $16M | $65M | Undisclosed | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $488K | 0% | 5 |
| 2025 | $488K | 0% | 7 |
| 2024 | $488K | 0% | 18 |
| 2023 | $488K | 0% | 20 |
| 2022 | $488K | 0% | 23 |
| 2021 | $488K | 0% | 20 |
| 2020 | $488K | — | — |
Growth signals
TargImmune Therapeutics website traffic
Latest recorded traffic for TargImmune Therapeutics is 90 monthly website visits, down 83.3% over the last three months. TargImmune Therapeutics's team declined 28.6% over the past year.
Comparisons
TargImmune Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
TargImmune Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on TargImmune Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where TargImmune Therapeutics has talent and traffic
team presence
In the news
Latest news about TargImmune Therapeutics
Recent press, funding announcements, and product moves mentioning TargImmune Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about TargImmune Therapeutics
An AI-synthesized read of the highest-engagement posts about TargImmune Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TargImmune Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.